NCT06253195 - BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

February 28, 2026

Study Completion Date

October 26, 2026

Conditions

Advanced Solid TumorMetastatic Solid TumorHormone-receptor-positive Breast CancerBreast CancerMetastatic Breast CancerHormone Receptor Positive Malignant Neoplasm of BreastHER2-negative Breast Cancer

Interventions

DRUG

BGB-43395

Administered orally.

DRUG

Fulvestrant

Administered via intramuscular injection.

DRUG

Letrozole

Administered orally.

Trial Locations (7)

100142

Beijing Cancer Hospital, Beijing

110001

The First Hospital of China Medical University, Shenyang

200000

Fudan University Shanghai Cancer Center, Shanghai

330006

The First Affiliated Hospital of Nanchang University Branch Donghu, Nanchang

350014

Fujian Cancer Hospital, Fuzhou

510245

Sun Yat Sen Memorial Hospital, Sun Yat Sen University (South), Guangzhou

530021

Guangxi Medical University Cancer Hospital, Nanning